RLC Labs Recalls Subpotent Nature Throid Thyroid Medication
RLC Labs Inc. is recalling Nature Throid thyroid medication because FDA analysis found the product to be subpotent.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 according to the rubric.
Plain-English summary
RLC Labs Inc. is recalling Nature Throid, 3/4 Grain (48.75 mg) Thyroid USP, a prescription-only medication containing Liothyronine (T3) and Levothyroxine (T4). The recall affects 100-count and 1000-count bottles manufactured by RLC Labs in Phoenix, Arizona.
The recall was initiated because FDA analysis determined that the product is subpotent, meaning it does not contain the full amount of active ingredient required by the United States Pharmacopeia (USP). The specific lot number is 109242, with an expiration date of 11/2022.
The product was distributed nationwide in the United States. Patients and healthcare providers should stop using the affected medication and contact their healthcare provider for guidance on alternative treatment options.
The recalled product
- Product
- Nature Throid, 3/4 Grain (48.75 mg) Thyroid USP [Liothyronine (T3) 6.75 mcg, Levothyroxine (T4) 28.5 mcg], packaged in a) 100-count bottles (NDC 64727-3302-1) and b) 1000-count bottles (NDC 64727-3302-2), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034
- Manufacturer
- RLC Labs Inc.
- Category
- Drug — Thyroid Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 109242
- Exp. Date 11/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 24 products in this recall →Related recalls
Same manufacturer · RLC Labs Inc.
See all →- ModerateRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- SevereRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- SeverePD-Rx Recalls Nature-Throid Tablets Due to CGMP Deviations and Sub-Potency Risk
FDA (Drugs) · 2020-10-14
- ModeratePreferred Pharmaceuticals Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-30
- ModeratePreferred Pharmaceuticals Recalls Nature-Throid Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2020-09-30
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Potency Variation and Dosage Failures
FDA (Drugs) · 2024-12-18
- CriticalAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine
FDA (Drugs) · 2020-10-28